Inhibitory effect of bone morphogenetic protein-2 on the proliferation of giant cell tumor of bone stromal cells in vitro

He,Baohua; He,Guanping; Zheng,Xiaofei; Li,Lihua; Li,Mei; Xia,Hong

doi:10.3892/etm.2015.2856

Inhibitory effect of bone morphogenetic protein-2 on the proliferation of giant cell tumor of bone stromal cells in vitro

Authors:
- Baohua He
- Guanping He
- Xiaofei Zheng
- Lihua Li
- Mei Li
- Hong Xia
View Affiliations

Affiliations: Department of Orthopedics, China Meitan General Hospital, Beijing 100028, P.R. China, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Orthopedics, Guangzhou Liu Hua Qiao Hospital, Guangzhou, Guangdong 510010, P.R. China
Published online on: November 12, 2015 https://doi.org/10.3892/etm.2015.2856
Pages: 309-314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The inhibitory effect of bone morphogenetic protein-2 (BMP-2) on the proliferation of giant cell tumor of bone stromal cells (GCTSCs) has not been fully elucidated. Therefore, the aim of this study was to evaluate the role of recombinant human BMP‑2 (rhBMP‑2) in the growth of GCTSCs. The effects of exposure to different concentrations of rhBMP‑2 (0, 10, 100 and 300 ng/ml) for 1, 3, 5 and 7 days on GCTSC proliferation were examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In addition, the effect of treatment with rhBMP‑2 (0 or 10 ng/ml) for 48 h on the cell cycle pattern of GCTSCs was examined by flow cytometry. The apoptosis‑inducing effect of rhBMP-2 (0 or 10 ng/ml) in GCTSCs was also determined by flow cytometry after 48 and 72 h. In addition, western blot assays were conducted to determine whether rhBMP‑2 acts on non‑Smad mitogen‑activated protein kinase (MAPK) signaling pathways, namely extracellular signal‑regulated kinase (ERK1/2), p38 and c‑jun‑N‑terminal kinase (JNK) pathways. The proliferation of GCTSCs treated with rhBMP‑2 (10, 100 or 300 ng/ml) for 5 or 7 days was significantly inhibited in a non dose-dependent and non-time-dependent manner (P<0.05). The treatment of GCTSCs with rhBMP‑2 (10 ng/ml) for 48 h had no effect on cell cycle distribution. The apoptosis of GCTSCs induced by exposure to rhBMP‑2 (10 ng/ml) for 48 or 72 h was significant (P<0.05). Expression levels of phospho‑ERK1/2, phospho‑p38 and phospho‑JNK increased significantly when GCTSCs were treated with rhBMP‑2 (10 ng/ml) for 72 h (P<0.05). The results indicate that rhBMP‑2 has no stimulatory effect on GCTSC growth. However, it may lead to the apoptosis of GCTSCs by non‑Smad MAPK signaling pathways.

View Figures

View References

1	Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP and Mendenhall NP: Giant cell tumor of bone. Am J Clin Oncol. 29:96–99. 2006. View Article : Google Scholar : PubMed/NCBI
2	Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P and Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356. 2003.PubMed/NCBI
3	Trieb K, Bitzan P, Lang S, Dominkus M and Kotz R: Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol. 27:200–202. 2001. View Article : Google Scholar : PubMed/NCBI
4	Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–114. 1987.PubMed/NCBI
5	Tse LF, Wong KC, Kumta SM, Huang L, Chow TC and Griffith JF: Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study. Bone. 42:68–73. 2008. View Article : Google Scholar : PubMed/NCBI
6	Gibbs CP, Lewis VO and Peabody T: Beyond bone grafting: Techniques in the surgical management of benign bone tumors. Instr Course Lect. 54:497–503. 2005.PubMed/NCBI
7	Zheng MH, Robbins P, Xu J, Huang L, Wood DJ and Papadimitriou JM: The histogenesis of giant cell tumour of bone: A model of interaction between neoplastic cells and osteoclasts. Histol Histopathol. 16:297–307. 2001.PubMed/NCBI
8	Hopkins DR, Keles S and Greenspan DS: The bone morphogenetic protein 1/Tolloid-like metalloproteinases. Matrix Biol. 26:508–523. 2007. View Article : Google Scholar : PubMed/NCBI
9	Senta H, Park H, Bergeron E, Drevelle O, Fong D, Leblanc E, Cabana F, Roux S, Grenier G and Faucheux N: Cell responses to bone morphogenetic proteins and peptides derived from them: Biomedical applications and limitations. Cytokine Growth Factor Rev. 20:213–222. 2009. View Article : Google Scholar : PubMed/NCBI
10	Singh A and Morris RJ: The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 21:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
11	Barboza E, Caúla A and Machado F: Potential of recombinant human bone morphogenetic protein-2 in bone regeneration. Implant Dent. 8:360–367. 1999. View Article : Google Scholar : PubMed/NCBI
12	Hogan BL: Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev. 10:1580–1594. 1996. View Article : Google Scholar : PubMed/NCBI
13	Chen A, Wang D, Liu X, He S, Yu Z and Wang J: Inhibitory effect of BMP-2 on the proliferation of breast cancer cells. Mol Med Rep. 6:615–620. 2012.PubMed/NCBI
14	Ye S, Park BH, Song KJ, Kim JR, Jang KY, Park HS, Bae JS, Brochmann EJ, Wang JC, Murray SS and Lee KB: In vivo inhibition of bone morphogenetic protein-2 on breast cancer cell growth. Spine (Phila Pa 1976). 38:E143–E150. 2013. View Article : Google Scholar : PubMed/NCBI
15	Langenfeld EM, Kong Y and Langenfeld J: Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 25:685–692. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kokorina NA, Lewis JS Jr, Zakharkin SO, Krebsbach PH and Nussenbaum B: rhBMP-2 has adverse effects on human oral carcinoma cell lines in vivo. Laryngoscope. 122:95–102. 2012. View Article : Google Scholar : PubMed/NCBI
17	Molina CA, Sarabia-Estrada R, Gokaslan ZL, Witham TF, Bydon A, Wolinsky JP and Sciubba DM: Delayed onset of paralysis and slowed tumor growth following in situ placement of recombinant human bone morphogenetic protein 2 within spine tumors in a rat model of metastatic breast cancer. J Neurosurg Spine. 16:365–372. 2012. View Article : Google Scholar : PubMed/NCBI
18	Haÿ E, Lemonnier J, Fromigué O, Guénou H and Marie PJ: Bone morphogenetic protein receptor IB signaling mediates apoptosis independently of differentiation in osteoblastic cells. J Biol Chem. 279:1650–1658. 2004. View Article : Google Scholar : PubMed/NCBI
19	Kimura N, Matsuo R, Shibuya H, Nakashima K and Taga T: BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem. 275:17647–17652. 2000. View Article : Google Scholar : PubMed/NCBI
20	Lee KS, Hong SH and Bae SC: Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene. 21:7156–7163. 2002. View Article : Google Scholar : PubMed/NCBI
21	Moustakas A and Heldin CH: Non-Smad TGF-beta signals. J Cell Sci. 118:3573–3584. 2005. View Article : Google Scholar : PubMed/NCBI
22	Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G and Caverzasio J: Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res. 18:2060–2068. 2003. View Article : Google Scholar : PubMed/NCBI
23	Huang L, Teng XY, Cheng YY, Lee KM and Kumta SM: Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone. 34:393–401. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kudo N, Ogose A, Ariizumi T, Kawashima H, Hotta T, Hatano H, Morita T, Nagata M, Siki Y, Kawai A, et al: Expression of bone morphogenetic proteins in giant cell tumor of bone. Anticancer Res. 29:2219–2225. 2009.PubMed/NCBI
25	Su YP, Chen WM and Chen TH: Giant-cell tumors of bone: An analysis of 87 cases. Int Orthop. 28:239–243. 2004.PubMed/NCBI
26	Saiz P, Virkus W, Piasecki P, Templeton A, Shott S and Gitelis S: Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Related Res. 424:221–226. 2004. View Article : Google Scholar
27	Ward WG Sr and Li G: Customized treatment algorithm for giant cell tumor of bone: Report of a series. Clin Orthop Relat Res. 397:259–270. 2002. View Article : Google Scholar : PubMed/NCBI
28	Turcotte RE, Wunder JS, Isler MH, Schachar N, Masri BA, Moreau G and Davis AM: Canadian Sarcoma Group: Giant cell tumor of bone. Giant cell tumor of long bone: A Canadian sarcoma group study. Clin Orthop Relat Res. 397:248–258. 2002. View Article : Google Scholar : PubMed/NCBI
29	Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Büchler MW and Korc M: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 116:1202–1216. 1999. View Article : Google Scholar : PubMed/NCBI
30	Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T and Terada M: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 57:5022–5027. 1997.PubMed/NCBI
31	Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY and Carethers JM: Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol. 291:G135–G145. 2006. View Article : Google Scholar : PubMed/NCBI
32	Wen XZ, Miyake S, Akiyama Y and Yuasa Y: BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun. 316:100–106. 2004. View Article : Google Scholar : PubMed/NCBI
33	Brubaker KD, Corey E, Brown LG and Vessella RL: Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem. 91:151–160. 2004. View Article : Google Scholar : PubMed/NCBI
34	Pouliot F, Blais A and Labrie C: Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res. 63:277–281. 2003.PubMed/NCBI